<DOC>
	<DOCNO>NCT00606489</DOCNO>
	<brief_summary>The primary objective study Caldolor administer hospitalize adult pediatric burn patient determine efficacy Caldolor reduce fever compare placebo administer every 6 hour least 24 hour .</brief_summary>
	<brief_title>Efficacy Safety Study Caldolor ( Intravenous Ibuprofen ) Hospitalized Adult Pediatric Burn Patients</brief_title>
	<detailed_description />
	<mesh_term>Burns</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1 . Patients second and/or third degree thermal burn cover 10 percent total body surface area ( include face ) anticipate hospital stay great 72 hour . 2 . Adequate intravenous access 3 . Have fever , documented temperature great equal 38.0 degree celsius ( 100.4 degree fahrenheit ) 1 . Patients electric burn 2 . Use acetaminophen , nonsteriodal antiinflammatory agent ( NSAIDs ) fever reduce medication within 4 hour prior dose 3 . Patients take warfarin lithium 4 . Active , clinically significant asthma 5 . History allergy hypersensitivity component intravenous ibuprofen , NSAIDs , aspirin ( related product ) , COX2 inhibitors 6 . Pregnant nursing 7 . History severe head trauma require current hospitalization , intracranial surgery stroke within previous 30 day , history intracerebral arteriovenous malformation , cerebral aneurism central nervous system mass lesion 8 . Have history congenital bleeding diathesis ( e.g . hemophilia ) active clinically significant bleeding , underlie platelet dysfunction include ( limited ) idiopathic thrombocytopenic purpura , disseminate intravascular coagulation , congenital platelet dysfunction 9 . Have gastrointestional bleeding require medical intervention within previous 6 week ( unless definitive surgery perform ) 10 . Have platelet count le 20,000 mm^3 11 . Be dialysis 12 . Be receive full dose anticoagulation therapy Activated Protein C within 6 hour dose ( clopidogrel , prophylaxis enoxaparin subcutaneous heparin acceptable ) 13 . Inability understand requirement study , willing provide write informed consent ( evidenced signature inform consent document approve Institutional Review Board [ IRB ] ) , agree abide study restriction ( If patient incapacitate , informed consent seek legally acceptable representative . ) 14 . Refusal provide write authorization use disclosure protect health information ( If patient incapacitate , informed consent seek legally acceptable representative . ) 15 . Have receive another investigational drug within past 30 day 16 . Be otherwise unsuitable study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>